Real-world healthcare resource utilization (HCRU) following chimeric antigen receptor (CAR) T-cell therapy in US patients treated in new authorized treatment centers (ATCs) without FACT accreditation.

e19515 Background: CAR T-cell therapy offers improved outcomes in lymphoid malignancies and multiple myeloma (MM), yet access is suboptimal due to a limited number of ATCs. In recent years, US expansion has included the launch of new ATCs, many opening without Foundation for the Accreditation of Cellular Therapy (FACT) accreditation. Real-world HCRU at these sites remain understudied. We examined post-infusion HCRU among patients treated at new US ATCs without FACT accreditation at the time of analysis. Methods: We conducted a retrospective analysis of HealthVerity Marketplace open claims (Jul 2023–Sep 2025). Adults (≥18 years) with CAR T-cell infusion at new ATCs without FACT accreditation were included, identified using procedure and billing codes. Outcomes assessed ≤30 days post-infusion were hospitalization length of stay (LOS), emergency department (ED) visits, 30-day readmission rates, and outpatient HCRU. Analyses were descriptive and limited to DLBCL and MM; other indications were included in the cohort but excluded from analyses due to small sample sizes. Results: A total of 55 patients across all indications received CAR T at 6 new ATCs. The cohort included 26 patients with diffuse large B-Cell lymphoma (DLBCL) (17/26 received axi-cel), 22 with MM (14/22 received ide-cel), and 7 with other hematologic cancers. Use of CAR T at new non-FACT ATCs increased over time (<11 patients in 2023; 16 in 2024; 34 in the first half of 2025). Mean age was 69.0 (DLBCL) and 68.5 (MM), and most patients were male. Infusion-related hospitalization, readmissions, and 30-day outpatient HCRU are summarized in the table. Conclusions: Delivery of CAR T at newly established, non-FACT accredited ATCs has increased over time, expanding patient access. Post-infusion HCRU appears consistent with prior reports, suggesting manageable resource needs. These early findings support the feasibility of expanding CAR T delivery to improve access even without FACT accreditation, with further evaluation of clinical outcomes and costs warranted. Utilization Category DLBCL among readmitted) 7.5 (5.9) / 5.5 (2-19) 8.5 (6.6) / 7 (2-19) 4.5 (2.1) / 4.5 (3-6) Outpatient utilization (≤ 30 days post-infusion) Number of physician visits 0.4 (0.7) / 0 (0-3) 0.3 (0.7) / 0 (0-3) 0.6 (0.6) / 1 (0-2) Number of ED visits <0.1 (0.1) / 0 (0-1) <0.1 (0.2) / 0 (0-1) 0 (0) / 0 (0-0) Number of outpatient services (e.g. lab, imaging) 1.7 (1.8) / 1 (0-7) 0.9 (1.3) / 0 (0-5) 2.6 (1.9) / 2 (0-7)